A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 905 participants.
Also called NCT02681094
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 905 participants
- Sponsor
- Registry
-
NCT02681094
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Germany, Mexico, Russia
- Registry status
- Completed
Technical summary
Registry record NCT02681094. Randomized; triple masking; primary purpose treatment. Start 2016-02-26 (actual); primary completion 2017-07-15 (actual). Results posted on 2018-10-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Inadequate Glycaemic Control
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo for Dapagliflozin
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Placebo for Saxagliptin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02681094- Content hash
ad4c066c4f21f3d8699a3b8e809bf8ca041151e70d1310368fdc4817cd3774eb